By the numbers: As the pandemic biotech boom fades, it's beginning to look a lot like 2019 — or before
This year, with Nasdaq iced over, everything is falling behind. A quick turn to CDER’s approvals for the year reveals that the group has stamped an OK on only 28 drugs, well behind the 42 recorded by this date in 2021. And with manufacturing inspections in China on hold, as well as the general lingering fallout from the pandemic, there are no signs of a comeback in the last two months of the year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters